5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Phase C, contributors will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment until disorder progression or maybe the participants are unable to tolerate the study drugs.- "Our study unveiled the important purpose of the KLF16/MYC regulatory axis in modulating tumor g